VaxInnate Corporation Reports Progress On Avian Influenza Vaccine; Early Testing Demonstrates Potency In A Standard Virus Inhibition Assay

CRANBURY, N.J.--(BUSINESS WIRE)--A vaccine candidate against the Vietnam H5N1 avian influenza virus has shown promising results in preclinical testing, according to a presentation made by VaxInnate Corporation at “The Changing Landscape of Vaccine Development” symposium, sponsored by the University of Texas Medical Branch (UTMB) in Galveston, Texas. VaxInnate reported that the vaccine is highly immunopotent and stimulates a virus-neutralizing antibody response against the H5N1 virus.